News

Viela Bio, Inc. and Mitsubishi Tanabe Pharma Corporation announced a collaboration focused on the development and commercialization of inebilizumab – Viela’s humanized anti-CD19…
Read More...

Alcami Corporation announced the launch of its new rapid sterility offering, a service that leverages cutting-edge microbiological testing technology to deliver significantly faster…
Read More...

Hoth Therapeutics, Inc. a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as…
Read More...

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces it has dosed its…
Read More...

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Beovu (brolucizumab) injection, also known as RTH258 for the treatment of wet age-related macular…
Read More...

GlaxoSmithKline plc announced a five-year collaboration with Lyell Immunopharma, a San Francisco biotechnology company, to develop new technologies to improve cell therapies for cancer…
Read More...

Pfenex Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the new drug application for PF708 submitted under the 505(b)(2) regulatory pathway, with Forteo…
Read More...

Akcea Therapeutics, and Pfizer announced that the companies have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being…
Read More...

AstraZeneca announced that the US Food and Drug Administration (FDA) has approved the self-administration of Fasenra (benralizumab) in a pre-filled, single-use auto-injector (the…
Read More...

Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, announced it entered…
Read More...

Prometheus Biosciences, Inc., a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and…
Read More...

Merck, known as MSD outside the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA) in…
Read More...

Elicio Therapeutics, a next generation immuno-oncology company, announced that it has closed its $33 million Series B financing. Proceeds from the financing will be used to advance…
Read More...

Lantheus Holdings, Inc., parent company of Lantheus Medical Imaging, Inc., a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and…
Read More...

Cellular Biomedicine Group, a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced it…
Read More...

GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional…
Read More...

Xylyx Bio announced the development of substrates for anti-fibrotic drug discovery as the next stage of its pipeline of pre-clinical cell culture products. Through the development of…
Read More...

Thermo Fisher Scientific announced the expansion of its API manufacturing capabilities following the completion of its previously announced acquisition of an active pharmaceutical…
Read More...

Astellas Pharma Inc. announced that it will invest nearly $13 million into two innovation incubators operated by LabCentral, a premier United States-based laboratory facility for…
Read More...

Elligo Health Research, a healthcare-enabling research organization, has received a grant from the U.S. Food and Drug Administration (FDA) for a follow-on project to extend the value of…
Read More...